Helaina has raised $69.6M in total across 4 funding rounds.
Helaina's investors include Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, Tom Williams, Jenny Fielding, Scott Hartley, Inspired Capital.
Helaina is a New York City-based biotechnology company founded in 2019 that develops precision fermentation technology to produce bio-identical human proteins, starting with effera™, a lactoferrin functionally equivalent to that in breast milk. It serves infant formula makers, consumer product brands, and broader nutrition markets by solving the problem of inaccessible bioactive human proteins, which support immune health and reduce inflammation—offering up to 400% better uptake than bovine alternatives and 63% inflammation reduction in studies[1][4]. The company has shown strong growth momentum: a $20M Series A in 2021 accelerated R&D, a $45M Series B in 2024 enabled commercialization, and by 2025, it reached metric-ton scale manufacturing with effera™ launching in products like dairy-free colostrum and cycle-syncing proteins[1][2][3].
Helaina's backstory stems from founder Laura Katz, a food scientist featured in Forbes' 30 Under 30, who was inspired by a podcast on the black market for breast milk, highlighting demand for its bioactive proteins among athletes and parents[1]. Before Helaina, Katz developed products for major food brands and saw precision fermentation's potential to recreate human glycoproteins using engineered yeast, rather than mere imitation[1][2]. Launched in 2019 on the premise of smarter nutrition via human proteins like lactoferrin, early traction came from proving production outside the body; pivotal moments include the 2021 Series A for tech stack development and 2024 Series B for scaling to commercial viability[1][3].
Helaina rides the precision fermentation wave in food tech, akin to cultured meat and alt-proteins, amid rising demand for bio-identical nutrition as consumers seek immune-supporting, sustainable alternatives to animal-derived ingredients[2][3][4]. Timing aligns with post-2024 funding recovery in food tech M&A, where buyers favor scalable biotech like Helaina's yeast-based glycoprotein production over extraction methods[3]. Market forces favoring it include regulatory acceptance of fermented proteins, global shortages of human milk components, and trends in personalized wellness (e.g., supplements for inflammation and uptake), positioning Helaina to influence ecosystems by ubiquitizing these proteins like vitamin C—potentially in all foods within 20 years[2]. It democratizes access, impacting startups via partnerships and accelerating human-aligned nutrition standards[1][4].
Helaina is poised to dominate bio-identical nutrition with effera™ as a platform ingredient, expanding from infants to everyday foods and wellness products amid precision bio trends. Regulatory wins, further scaling (building on 2025 milestones), and B2B partnerships will drive revenue, while M&A appetite in lean food tech funding favors its trajectory[3][4]. Its influence may evolve by setting new benchmarks for functional proteins, enabling broader immune health innovations. From Katz's podcast spark to metric-ton reality, Helaina proves technology can unlock the body's innate power for all[1].
Helaina has raised $69.6M across 4 funding rounds. Most recently, it raised $45.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $45.0M Series B | Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, Tom Williams | |
| Nov 1, 2021 | $20.0M Series A | Jenny Fielding, Scott Hartley, Inspired Capital, Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, Tom Williams | |
| Aug 1, 2020 | $4.0M Seed | Jenny Fielding, Scott Hartley, Plum Alley Investments, Primary Venture Partners, Spark Capital, Hannah Bronfman, Scott Belsky, Tom Williams | |
| Aug 1, 2019 | $600K Seed | Jenny Fielding, Scott Hartley |
